D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Price:
57.16
CNY
3.21%
Market Closed
Market Cap:
¥26.6B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
D
|
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
|
CN |
|
Aena SME SA
OTC:ANNSF
|
ES |
|
C
|
China Shineway Pharmaceutical Group Ltd
HKEX:2877
|
CN |
Income Statement
Earnings Waterfall
Dizal Jiangsu Pharmaceutical Co Ltd
Dizal Jiangsu Pharmaceutical Co Ltd
Income Statement
Dizal Jiangsu Pharmaceutical Co Ltd
Dizal Jiangsu Pharmaceutical Co Ltd
Currency: CNY
| Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||
| Interest Expense |
3
|
4
|
4
|
4
|
4
|
4
|
6
|
8
|
11
|
15
|
19
|
23
|
27
|
0
|
0
|
|
| Revenue |
10
N/A
|
7
-30%
|
4
-49%
|
0
N/A
|
0
N/A
|
0
N/A
|
40
N/A
|
91
+128%
|
173
+89%
|
295
+71%
|
390
+32%
|
360
-8%
|
438
+22%
|
511
+17%
|
608
+19%
|
|
| Gross Profit | ||||||||||||||||
| Cost of Revenue |
(9)
|
(6)
|
(3)
|
0
|
(0)
|
(1)
|
(2)
|
(3)
|
(6)
|
(10)
|
(11)
|
(9)
|
(17)
|
(22)
|
(30)
|
|
| Gross Profit |
1
N/A
|
1
-37%
|
0
-69%
|
0
N/A
|
(0)
N/A
|
(1)
-20%
|
38
N/A
|
88
+134%
|
166
+89%
|
285
+71%
|
379
+33%
|
351
-7%
|
422
+20%
|
489
+16%
|
578
+18%
|
|
| Operating Income | ||||||||||||||||
| Operating Expenses |
(720)
|
(744)
|
(755)
|
(786)
|
(839)
|
(939)
|
(1 116)
|
(1 213)
|
(1 270)
|
(1 312)
|
(1 304)
|
(1 283)
|
(1 319)
|
(1 366)
|
(1 443)
|
|
| Selling, General & Administrative |
(90)
|
(94)
|
(106)
|
(119)
|
(197)
|
(274)
|
(364)
|
(427)
|
(471)
|
(521)
|
(563)
|
(584)
|
(628)
|
(661)
|
(700)
|
|
| Research & Development |
(613)
|
(636)
|
(649)
|
(612)
|
(653)
|
(678)
|
(763)
|
(745)
|
(854)
|
(845)
|
(794)
|
(664)
|
(729)
|
(749)
|
(800)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
(63)
|
0
|
0
|
0
|
(73)
|
0
|
0
|
0
|
(76)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
(16)
|
(14)
|
(0)
|
7
|
11
|
13
|
12
|
32
|
56
|
54
|
54
|
41
|
38
|
45
|
57
|
|
| Operating Income |
(718)
N/A
|
(743)
-3%
|
(755)
-2%
|
(786)
-4%
|
(840)
-7%
|
(940)
-12%
|
(1 078)
-15%
|
(1 125)
-4%
|
(1 103)
+2%
|
(1 027)
+7%
|
(925)
+10%
|
(933)
-1%
|
(898)
+4%
|
(877)
+2%
|
(865)
+1%
|
|
| Pre-Tax Income | ||||||||||||||||
| Interest Income Expense |
2
|
28
|
42
|
50
|
46
|
34
|
23
|
17
|
11
|
1
|
(5)
|
(9)
|
(13)
|
(11)
|
(8)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(716)
N/A
|
(716)
+0%
|
(713)
+0%
|
(736)
-3%
|
(794)
-8%
|
(905)
-14%
|
(1 055)
-17%
|
(1 108)
-5%
|
(1 092)
+1%
|
(1 026)
+6%
|
(928)
+9%
|
(940)
-1%
|
(909)
+3%
|
(886)
+3%
|
(873)
+2%
|
|
| Net Income | ||||||||||||||||
| Tax Provision |
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
|
| Income from Continuing Operations |
(716)
|
(716)
|
(714)
|
(736)
|
(794)
|
(905)
|
(1 055)
|
(1 108)
|
(1 092)
|
(1 026)
|
(928)
|
(940)
|
(909)
|
(886)
|
(873)
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
88
|
91
|
94
|
95
|
8
|
6
|
|
| Net Income (Common) |
(716)
N/A
|
(716)
0%
|
(714)
+0%
|
(736)
-3%
|
(794)
-8%
|
(905)
-14%
|
(1 055)
-17%
|
(1 108)
-5%
|
(1 092)
+1%
|
(938)
+14%
|
(837)
+11%
|
(846)
-1%
|
(814)
+4%
|
(879)
-8%
|
(867)
+1%
|
|
| EPS (Diluted) |
-1.77
N/A
|
-1.78
-1%
|
-1.77
+1%
|
-1.82
-3%
|
-1.96
-8%
|
-2.23
-14%
|
-2.59
-16%
|
-2.72
-5%
|
-2.63
+3%
|
-2.25
+14%
|
-2.04
+9%
|
-2.04
N/A
|
-1.96
+4%
|
-1.95
+1%
|
-1.92
+2%
|
|
Switch to:
Switch to:
See Also
Discover More
